Third-generation EGFR inhibitors, like Osimertinib, used in EGFR-mutated non-small cell lung cancer, specifically targeting the mutated kinase domains, are ineffective in EGFR-amplified or EGFRvIII-mutated GBM [25,26]. Here, EGFR is linked to non-small cell lung carcinoma.